At the request of our customer, this cross-linked HA product incorporates peptides for various therapeutic applications. For the manufacture of preclinical batches, our team relies on a strong partnership with our customer, and takes the necessary steps to understand the specificities of this formulation.
Company
Development of a cross-linked HA formulation containing peptides
Explore our environment
-
Financing the future: SyrhaTech aims for new heights
No company is more future-oriented at the moment than SyrhaTech: a Biotech medical device company…
-
SyrhaTech supports organization of ISHAS’s awards
For the past four months, SyrhaTech has been in partnership with the learned society ISHAS…
-
SyrhaTech, an aesthetic medical device company, between France and Switzerland
The SyrhaTech team is made up of people from Europe’s four corners. Everyone is very…
-
SyrhaTech joins CDMO France
SyrhaTech is proud to announce that we have joined the “CDMO France” association. CDMO France…
-
They Trust SyrHA : The Excellence of a CDMO
At SyrHA, we believe that the cornerstone of our success is the unwavering trust that…
-
Announcing strategic partnership : SyrHA the CDMO and ISHAS organization
We are pleased to inform you that SyrHA has joined the International Society for Hyaluronic…
-
CDMO: Evolution of their role
Innovative biopharmaceutical companies are increasingly engaging in strategic partnerships with CDMOs, whereas in the past,…
-
Join us at IMCAS Paris!
We’re delighted to announce that our team will be taking part in the IMCAS 2024…
-
SyrHATech is thrilled to install its new autoclave!
In the field of sterile medical device manufacturing, the terminal sterilization of your products is…
-
SyrHATech goes to CPHI Barcelona – from 10/24 to 10/26
The CPHI (Convention on Pharmaceutical Ingredients) is the reference event for the pharmaceutical industry. Itinerant…
